Sorafenib For Treating Head And Neck Adenocarcinoma Of Unknown Primary Site: A Case Report
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH(2020)
摘要
The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular endothelial growth factor A amplification and the TP53 R209Kfs mutation. Treatment with the multi-targeted protein kinase inhibitor sorafenib controlled the patient's symptoms and improved his quality of life.
更多查看译文
关键词
Cancer of unknown primary, adenocarcinoma, head and neck cancer, sorafenib, adverse events, next-generation sequencing
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要